Genmab Revels In Darzalex' Success; 2018 Is The Year To Watch
This article was originally published in Scrip
Executive Summary
One quarter on from Gemnab's Darzalex (daratumumab) becoming the first monoclonal antibody ever approved for the treatment of multiple myeloma and the first human CD38 antibody to secure a regulatory nod worldwide, the company's full year earnings presentation focused heavily on the drug's prospects in 2016 and onwards.